Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason R Brown

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Clinical Genitourinary Cancer|May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology SubtypesDimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Clinical Genitourinary Cancer|May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology SubtypesDimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Pageof 8